GlassScriptPhysician profile
David A Bond
NPI 1114288859
$30,084.65
in general payments reported to CMS, 2019-2025
16 companies · $1,859 in 2025
The $1,859 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,545 · 2021: $11K · 2022: $1,443 · 2023: $11K · 2024: $2,608 · 2025: $1,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $830 · Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,812.50 |
| Travel and Lodging | $830.37 |
| Food and Beverage | $805.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $10,984.17 | 2023-2024 | |
| Seagen INC. | $10,336.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $3,492.56 | 2019-2024 | |
| Kite Pharma, INC. | $3,260.00 | 2021 | |
| Incyte Corporation | $1,650.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $153.67 | 2023-2025 | Calquence |
| Genmab U.S., INC. | $133.45 | 2023-2024 | Epkinly |
| Genentech USA, INC. | $74.16 | 2025 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.